Replies to post #127557 on Biotech Values

[DewDiligence]

The Xarelto results in ACS are not a clear win—from the newswire you posted:

Patients who took Xarelto faced a higher risk of major bleeding.

Pending presentation of the full dataset from this study, I’m making no changes to the arithmetic in #msg-67368764.